Long-term protective efficacy of the Escherichia coli-produced HPV-16/18 bivalent human papillomavirus vaccine in women vaccinated at 18–45 years: A 9-year follow-up study
Vaccination with the bivalent HPV vaccine offers long-term protection against HPV-16/18 infections for at least 9 years.
Authors
- You‐Lin Qiao (ORCID: https://orcid.org/0000-0001-6380-0871)
- Xinhua Jia (ORCID: https://orcid.org/0000-0002-8399-6637)
- Shangying Hu (ORCID: https://orcid.org/0000-0002-4778-1612)
- Xuefeng Kuang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Infectious Medicine
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1016/j.imj.2025.100164
- Citations
- 2
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Tencent